Assessing the Value of New Antibiotics- Creating a Value Assessment Framework

Published Nov 8, 2017
Glasgow, Scotland, UK—8 November 2017—ISPOR, the professional society for health economics and outcomes research (HEOR), held an important discussion on the challenges inherent in assessing new antibiotics in a world facing the growing threat of antibiotic resistance. The issue panel was held this morning at ISPOR’s 20th Annual European Congress in Glasgow, Scotland, UK. The issue panel, “How Can We Assess the Value of New Antibiotics?” [IP22], was moderated by Chris Henshall, PhD, Office of Health Economics, London, UK. Speakers included Alec Morton, PhD, University of Strathclyde, Glasgow, Scotland, UK; Douglas Lundin, PhD, TLV (Swedish Dental and Pharmaceutical Reimbursement Agency), Stockholm, Sweden; and Adrian Towse, MA, MPhil, Office of Health Economics, London, UK. In this session, speakers explored the challenges assessors have in evaluating new antibiotics that are beginning to come to market following international initiatives designed to boost research and development in response to the urgent need for new antibiotics. Speakers discussed the need for health technology assessment and payer bodies to be able to assess the value of these new antibiotics so that prices and payment mechanisms can provide both appropriate access for patients and return-on-investment for developers. Adrian Towse, MA, MPhil presented work from the Office of Health Economics on developing a value framework for antibiotics, building on a recent discussion forum in London with key stakeholders. Alec Morton, PhD provided an update on the findings of the DRIVE-AB project (funded by the European Commission and EFPIA), which aims to provide an approach for the assessment of the value of an antibiotic. Douglas Lundin, PhD reflected on the challenges for payers, health systems, and governments and the ways that these challenges can be addressed. Additional information on the ISPOR 20th Annual European Congress can be found here. Released presentations from the congress can be found here. Interested parties can follow news and developments from the congress on social media using the hashtag #ISPORGlasgow.


  ABOUT ISPOR ISPOR, the professional society for health economics and outcomes research (HEOR), is an international, multistakeholder, nonprofit dedicated to advancing HEOR excellence to improve decision making for health globally. The Society is the leading source for scientific conferences, peer-reviewed and MEDLINE-indexed publications, good practices guidance, education, collaboration, and tools/resources in the field. Web: | LinkedIn: | Twitter: (@ISPORorg) | YouTube: | Facebook:

Related Stories

Measuring What Matters: Broadening the Scope of Health Economics Evaluation to Incorporate Well-Being

Jul 9, 2024

ISPOR announced the publication of a special themed section of research papers in Value in Health that offer insights into facets of economic evaluation aimed to incorporate well-being into decision making.

Confronting the Backlash Against QALYs: Key Insights From Leading Health Economists

Jun 18, 2024

ISPOR announced the publication of a collection of papers that examine the long-standing debate surrounding the use of quality-adjusted life years (QALYs) and alternative measures in healthcare decision making.

ISPOR Good Practices Report Offers Guidance for Using Real-World Data From EHRs in Health Technology Assessments

Jun 17, 2024

ISPOR announced the publication of an ISPOR Good Practices Report that proposes a framework for assessing the suitability of electronic health records data for use in health technology assessments. The report, “Assessing Real-World Data from Electronic Health Records for Health Technology Assessment: The SUITABILITY Checklist: A Good Practices Report of an ISPOR Task Force” was published in the June 2024 issue of Value in Health.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on Update my browser now